121 related articles for article (PubMed ID: 16572838)
1. [Study on immunogenicity of the N-terminal polypeptide of RTX toxin I of Actinobacillus pleuropneumoniae].
Mei L; Zhou R; Lu HS; Bei WC; Liu WH; Lin LW; Hong WZ; Chen HC
Sheng Wu Gong Cheng Xue Bao; 2006 Jan; 22(1):39-45. PubMed ID: 16572838
[TBL] [Abstract][Full Text] [Related]
2. [Acute toxicity and immunoprotection of recombinant apxI toxin of Actinobacillus pleuropneumoniae in mice].
Yan KX; Liu JJ; Zhou R; Wu B; Liu WH; Chen HC
Sheng Wu Gong Cheng Xue Bao; 2006 Jan; 22(1):65-70. PubMed ID: 16572842
[TBL] [Abstract][Full Text] [Related]
3. [Cloning and expression of hemolytic-toxin from Actinobacillus pleuropneumoniae and the immunoprotection in mice].
Du A; Diao Y; Zhang W; Zhang R; Zang D; Liu F
Wei Sheng Wu Xue Bao; 2008 Mar; 48(3):342-8. PubMed ID: 18479061
[TBL] [Abstract][Full Text] [Related]
4. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs.
Shin MK; Kang ML; Jung MH; Cha SB; Lee WJ; Kim JM; Kim DH; Yoo HS
Vet Immunol Immunopathol; 2013 Jan; 151(1-2):132-9. PubMed ID: 23206402
[TBL] [Abstract][Full Text] [Related]
5. Nasal immunization with major epitope-containing ApxIIA toxin fragment induces protective immunity against challenge infection with Actinobacillus pleuropneumoniae in a murine model.
Seo KW; Kim SH; Park J; Son Y; Yoo HS; Lee KY; Jang YS
Vet Immunol Immunopathol; 2013 Jan; 151(1-2):102-12. PubMed ID: 23200821
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of multicomponent recombinant vaccines against Actinobacillus pleuropneumoniae in mice.
Shao M; Wang Y; Wang C; Guo Y; Peng Y; Liu J; Li G; Liu H; Liu S
Acta Vet Scand; 2010 Sep; 52(1):52. PubMed ID: 20831818
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice.
Shin SJ; Shin SW; Kang ML; Lee DY; Yang MS; Jang YS; Yoo HS
J Vet Sci; 2007 Dec; 8(4):383-92. PubMed ID: 17993753
[TBL] [Abstract][Full Text] [Related]
8. Development of
Jung M; Won H; Shin MK; Oh MW; Shim S; Yoon I; Yoo HS
J Vet Sci; 2019 Mar; 20(2):e2. PubMed ID: 30944525
[TBL] [Abstract][Full Text] [Related]
9. Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae.
Xu F; Chen X; Shi A; Yang B; Wang J; Li Y; Guo X; Blackall PJ; Yang H
Vet Microbiol; 2006 Dec; 118(3-4):230-9. PubMed ID: 16930871
[TBL] [Abstract][Full Text] [Related]
10. The N-terminal domain of RTX toxin ApxI of Actinobacillus pleuropneumoniae elicits protective immunity in mice.
Seah JN; Frey J; Kwang J
Infect Immun; 2002 Nov; 70(11):6464-7. PubMed ID: 12379729
[TBL] [Abstract][Full Text] [Related]
11. Protection of mice against challenge with homologous and heterologous serovars of Actinobacillus pleuropneumoniae after live vaccination.
Prideaux CT; Pierce L; Krywult J; Hodgson AL
Curr Microbiol; 1998 Nov; 37(5):324-32. PubMed ID: 9767712
[TBL] [Abstract][Full Text] [Related]
12. Functional pentameric formation via coexpression of the Escherichia coli heat-labile enterotoxin B subunit and its fusion protein subunit with a neutralizing epitope of ApxIIA exotoxin improves the mucosal immunogenicity and protection against challenge by Actinobacillus pleuropneumoniae.
Kim JM; Park SM; Kim JA; Park JA; Yi MH; Kim NS; Bae JL; Park SG; Jang YS; Yang MS; Kim DH
Clin Vaccine Immunol; 2011 Dec; 18(12):2168-77. PubMed ID: 22030372
[TBL] [Abstract][Full Text] [Related]
13. [Construction and immunogenicity of an attenuated mutant of Actinobacillus pleuropneumoniae by insertional inactivation of apxIC].
Xu FZ; Shi AH; Chen XL; Yang B; Wang JL
Wei Sheng Wu Xue Bao; 2007 Oct; 47(5):923-7. PubMed ID: 18062275
[TBL] [Abstract][Full Text] [Related]
14. Molecular investigation of the role of ApxI and ApxII in the virulence of Actinobacillus pleuropneumoniae serotype 5.
Reimer D; Frey J; Jansen R; Veit HP; Inzana TJ
Microb Pathog; 1995 Mar; 18(3):197-209. PubMed ID: 7565014
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of Actinobacillus ApxIA toxin epitopes fused to the E. coli heat-labile enterotoxin B subunit.
Bagdasarian MM; Nagai M; Frey J; Bagdasarian M
Vaccine; 1999 Feb; 17(5):441-7. PubMed ID: 10073721
[TBL] [Abstract][Full Text] [Related]
16. Recombinant ApxIV protein enhances protective efficacy against Actinobacillus pleuropneumoniae in mice and pigs.
Wu HC; Yeh PH; Hsueh KJ; Yang WJ; Chu CY
J Appl Microbiol; 2018 Jun; 124(6):1366-1376. PubMed ID: 29431246
[TBL] [Abstract][Full Text] [Related]
17. Association of the CAMP phenomenon in Actinobacillus pleuropneumoniae with the RTX toxins ApxI, ApxII and ApxIII.
Frey J; Kuhn R; Nicolet J
FEMS Microbiol Lett; 1994 Dec; 124(2):245-51. PubMed ID: 7813893
[TBL] [Abstract][Full Text] [Related]
18. Structural analysis of the Actinobacillus pleuropneumoniae-RTX-toxin I (ApxI) operon.
Jansen R; Briaire J; Kamp EM; Gielkens AL; Smits MA
Infect Immun; 1993 Sep; 61(9):3688-95. PubMed ID: 8359891
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model.
Chiang CH; Huang WF; Huang LP; Lin SF; Yang WJ
Vaccine; 2009 Jul; 27(34):4565-70. PubMed ID: 19520199
[TBL] [Abstract][Full Text] [Related]
20. Genetic and antigenic characteristics of ApxIIA and ApxIIIA from Actinobacillus pleuropneumoniae serovars 2, 3, 4, 6, 8 and 15.
To H; Nagai S; Iwata A; Koyama T; Oshima A; Tsutsumi N
Microbiol Immunol; 2016 Jul; 60(7):447-58. PubMed ID: 27211905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
